肿瘤相关巨噬细胞：膀胱癌治疗靶点的前沿探索与研究新动态
Tumor-Associated Macrophages: Frontier Exploration and New Research Trends of Bladder Cancer Therapy Targets
DOI: 10.12677/acm.2025.1561804, PDF,   
作者: 刘振华*, 郝亮亮, 赵家伟, 武超越, 马锦容, 胡耀强：延安大学延安医学院，陕西 延安；靳永胜#：延安大学附属医院泌尿外科，陕西 延安
关键词: 膀胱癌；肿瘤微环境；肿瘤相关巨噬细胞；靶向治疗；Bladder Cancer； Tumor Microenvironment； Tumor-Associated Macrophages； Targeted Therapy
摘要: 膀胱癌是泌尿系统中最常见的恶性肿瘤之一，尽管现有的治疗手段包括手术、化疗和免疫疗法等，但晚期膀胱癌患者的总体生存率仍然较低。近年来，肿瘤微环境成为研究热点，尤其是肿瘤相关巨噬细胞在膀胱癌进展中的作用。肿瘤相关巨噬细胞在肿瘤微环境中通过促进肿瘤生长、转移和免疫逃逸，显著影响膀胱癌的预后。本文综述了肿瘤相关巨噬细胞的来源、极化及其对膀胱癌的影响，重点探讨了肿瘤相关巨噬细胞作为抗肿瘤免疫治疗靶点的潜力。未来的研究应进一步探索肿瘤相关巨噬细胞在膀胱癌中的具体机制，并开发更有效的靶向治疗方案，以改善患者的预后和生活质量。
Abstract: Bladder cancer is one of the most common malignant tumors in the urinary system. Although existing treatment methods include surgery, chemotherapy, and immunotherapy, the overall survival rate of patients with advanced bladder cancer remains low. In recent years, the tumor microenvironment has become a research hotspot, particularly the role of tumor-associated macrophages in the progression of bladder cancer. Tumor-associated macrophages significantly affect the prognosis of bladder cancer by promoting tumor growth, metastasis, and immune escape within the tumor microenvironment. This article reviews the origin, polarization of tumor-associated macrophages, and their impacts on bladder cancer, with a focus on discussing the potential of tumor-associated macrophages as targets for anti-tumor immunotherapy. Future research should further explore the specific mechanisms of tumor-associated macrophages in bladder cancer and develop more effective targeted therapy regimens to improve patients’ prognosis and quality of life.
文章引用：刘振华, 郝亮亮, 赵家伟, 武超越, 马锦容, 胡耀强, 靳永胜. 肿瘤相关巨噬细胞：膀胱癌治疗靶点的前沿探索与研究新动态[J]. 临床医学进展, 2025, 15(6): 899-906. https://doi.org/10.12677/acm.2025.1561804

参考文献

[1] Dyrskjøt, L., Hansel, D.E., Efstathiou, J.A., Knowles, M.A., Galsky, M.D., Teoh, J., et al. (2023) Bladder Cancer. Nature Reviews Disease Primers, 9, Article No. 58. [Google Scholar] [CrossRef] [PubMed]
[2] Kamat, A.M., Hahn, N.M., Efstathiou, J.A., Lerner, S.P., Malmström, P., Choi, W., et al. (2016) Bladder Cancer. The Lancet, 388, 2796-2810. [Google Scholar] [CrossRef] [PubMed]
[3] Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., et al. (2020) Tumor Microenvironment Complexity and Therapeutic Implications at a Glance. Cell Communication and Signaling, 18, Article No. 59. [Google Scholar] [CrossRef] [PubMed]
[4] DeNardo, D.G. and Ruffell, B. (2019) Macrophages as Regulators of Tumour Immunity and Immunotherapy. Nature Reviews Immunology, 19, 369-382. [Google Scholar] [CrossRef] [PubMed]
[5] Chen, Y., Song, Y., Du, W., Gong, L., Chang, H. and Zou, Z. (2019) Tumor-Associated Macrophages: An Accomplice in Solid Tumor Progression. Journal of Biomedical Science, 26, Article No. 78. [Google Scholar] [CrossRef] [PubMed]
[6] Zhao, L., Wang, Z., Tan, Y., Ma, J., Huang, W., Zhang, X., et al. (2024) Il-17A/CEBPβ/OPN/LYVE-1 Axis Inhibits Anti-Tumor Immunity by Promoting Tumor-Associated Tissue-Resident Macrophages. Cell Reports, 43, Article 115039. [Google Scholar] [CrossRef] [PubMed]
[7] Pan, Y., Yu, Y., Wang, X. and Zhang, T. (2020) Tumor-Associated Macrophages in Tumor Immunity. Frontiers in Immunology, 11, Article 583084. [Google Scholar] [CrossRef] [PubMed]
[8] O’Neill, L.A.J., Kishton, R.J. and Rathmell, J. (2016) A Guide to Immunometabolism for Immunologists. Nature Reviews Immunology, 16, 553-565. [Google Scholar] [CrossRef] [PubMed]
[9] Zhu, S., Yi, M., Wu, Y., Dong, B. and Wu, K. (2021) Roles of Tumor-Associated Macrophages in Tumor Progression: Implications on Therapeutic Strategies. Experimental Hematology & Oncology, 10, Article No. 60. [Google Scholar] [CrossRef] [PubMed]
[10] Murray, P.J. (2017) Macrophage Polarization. Annual Review of Physiology, 79, 541-566. [Google Scholar] [CrossRef] [PubMed]
[11] Annamalai, R.T., Turner, P.A., Carson, W.F., Levi, B., Kunkel, S. and Stegemann, J.P. (2018) Harnessing Macrophage-Mediated Degradation of Gelatin Microspheres for Spatiotemporal Control of BMP2 Release. Biomaterials, 161, 216-227. [Google Scholar] [CrossRef] [PubMed]
[12] Chanmee, T., Ontong, P., Konno, K. and Itano, N. (2014) Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment. Cancers, 6, 1670-1690. [Google Scholar] [CrossRef] [PubMed]
[13] Li, M., Cui, Y., Qi, Q., Liu, J., Li, J., Huang, G., et al. (2024) SPOP Downregulation Promotes Bladder Cancer Progression Based on Cancer Cell-Macrophage Crosstalk via STAT3/CCL2/IL-6 Axis and Is Regulated by Vezf1. Theranostics, 14, 6543-6559. [Google Scholar] [CrossRef] [PubMed]
[14] Qi, D., Lu, Y., Qu, H., Dong, Y., Jin, Q., Sun, M., et al. (2024) Independent Prognostic Value of CLDN6 in Bladder Cancer Based on M2 Macrophages Related Signature. iScience, 27, Article 109138. [Google Scholar] [CrossRef] [PubMed]
[15] Kessenbrock, K., Plaks, V. and Werb, Z. (2010) Matrix Metalloproteinases: Regulators of the Tumor Microenvironment. Cell, 141, 52-67. [Google Scholar] [CrossRef] [PubMed]
[16] Nagumo, Y., Kandori, S., Tanuma, K., Nitta, S., Chihara, I., Shiga, M., et al. (2021) PLD1 Promotes Tumor Invasion by Regulation of MMP-13 Expression via NF-κB Signaling in Bladder Cancer. Cancer Letters, 511, 15-25. [Google Scholar] [CrossRef] [PubMed]
[17] Guo, Y., Li, Z., Sun, W., Gao, W., Liang, Y., Mei, Z., et al. (2022) M2 Tumor Associate Macrophage-(TAM-) Derived LncRNA HISLA Promotes EMT Potential in Bladder Cancer. Journal of Oncology, 2022, Article 8268719. [Google Scholar] [CrossRef] [PubMed]
[18] Xu, Y., Zeng, H., Jin, K., Liu, Z., Zhu, Y., Xu, L., et al. (2022) Immunosuppressive Tumor-Associated Macrophages Expressing Interlukin-10 Conferred Poor Prognosis and Therapeutic Vulnerability in Patients with Muscle-Invasive Bladder Cancer. Journal for ImmunoTherapy of Cancer, 10, e003416. [Google Scholar] [CrossRef] [PubMed]
[19] Yu, Y., Liang, Y., Xie, F., Zhang, Z., Zhang, P., Zhao, X., et al. (2024) Tumor-Associated Macrophage Enhances PD-L1-Mediated Immune Escape of Bladder Cancer through PKM2 Dimer-STAT3 Complex Nuclear Translocation. Cancer Letters, 593, Article 216964. [Google Scholar] [CrossRef] [PubMed]
[20] Cheng, M., Chen, S., Li, K., Wang, G., Xiong, G., Ling, R., et al. (2024) CD276-Dependent Efferocytosis by Tumor-Associated Macrophages Promotes Immune Evasion in Bladder Cancer. Nature Communications, 15, Article No. 2818. [Google Scholar] [CrossRef] [PubMed]
[21] Nian, Z., Dou, Y., Shen, Y., Liu, J., Du, X., Jiang, Y., et al. (2024) Interleukin-34-Orchestrated Tumor-Associated Macrophage Reprogramming Is Required for Tumor Immune Escape Driven by P53 Inactivation. Immunity, 57, 2344-2361.E7. [Google Scholar] [CrossRef] [PubMed]
[22] Koll, F.J., Banek, S., Kluth, L., Köllermann, J., Bankov, K., Chun, F.K.-H., et al. (2023) Tumor-Associated Macrophages and Tregs Influence and Represent Immune Cell Infiltration of Muscle-Invasive Bladder Cancer and Predict Prognosis. Journal of Translational Medicine, 21, Article No. 124. [Google Scholar] [CrossRef] [PubMed]
[23] Sun, M., Zeng, H., Jin, K., Liu, Z., Hu, B., Liu, C., et al. (2022) Infiltration and Polarization of Tumor-Associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer. Cancer Immunology, Immunotherapy, 71, 1497-1506. [Google Scholar] [CrossRef] [PubMed]
[24] Qu, G., Liu, Z., Yang, G., Xu, Y., Xiang, M. and Tang, C. (2021) Development of a Prognostic Index and Screening of Prognosis Related Genes Based on an Immunogenomic Landscape Analysis of Bladder Cancer. Aging, 13, 12099-12112. [Google Scholar] [CrossRef] [PubMed]
[25] Tian, L., Yi, X., Dong, Z., Xu, J., Liang, C., Chao, Y., et al. (2018) Calcium Bisphosphonate Nanoparticles with Chelator-Free Radiolabeling to Deplete Tumor-Associated Macrophages for Enhanced Cancer Radioisotope Therapy. ACS Nano, 12, 11541-11551. [Google Scholar] [CrossRef] [PubMed]
[26] Coscia, M., Quaglino, E., Iezzi, M., Curcio, C., Pantaleoni, F., Riganti, C., et al. (2010) Zoledronic Acid Repolarizes Tumour-Associated Macrophages and Inhibits Mammary Carcinogenesis by Targeting the Mevalonate Pathway. Journal of Cellular and Molecular Medicine, 14, 2803-2815. [Google Scholar] [CrossRef] [PubMed]
[27] del Mar Maldonado, M., Schlom, J. and Hamilton, D.H. (2023) Blockade of Tumor-Derived Colony-Stimulating Factor 1 (CSF1) Promotes an Immune-Permissive Tumor Microenvironment. Cancer Immunology, Immunotherapy, 72, 3349-3362. [Google Scholar] [CrossRef] [PubMed]
[28] Li, Z., Ding, Y., Liu, J., Wang, J., Mo, F., Wang, Y., et al. (2022) Depletion of Tumor Associated Macrophages Enhances Local and Systemic Platelet-Mediated Anti-PD-1 Delivery for Post-Surgery Tumor Recurrence Treatment. Nature Communications, 13, Article No. 1845. [Google Scholar] [CrossRef] [PubMed]
[29] Chen, C., He, W., Huang, J., Wang, B., Li, H., Cai, Q., et al. (2018) LNMAT1 Promotes Lymphatic Metastasis of Bladder Cancer via CCL2 Dependent Macrophage Recruitment. Nature Communications, 9, Article No. 3826. [Google Scholar] [CrossRef] [PubMed]
[30] Yang, H., Zhang, Q., Xu, M., Wang, L., Chen, X., Feng, Y., et al. (2020) CCL2-CCR2 Axis Recruits Tumor Associated Macrophages to Induce Immune Evasion through PD-1 Signaling in Esophageal Carcinogenesis. Molecular Cancer, 19, Article No. 41. [Google Scholar] [CrossRef] [PubMed]
[31] Chiang, Y., Lu, L., Tsai, C., Tsai, Y., Wang, C., Hsueh, F., et al. (2024) C-C Chemokine Receptor 4 (CCR4)-Positive Regulatory T Cells Interact with Tumor-Associated Macrophages to Facilitate Metastatic Potential after Radiation. European Journal of Cancer, 198, Article 113521. [Google Scholar] [CrossRef] [PubMed]
[32] Lu, G. and Qiu, Y. (2023) Spi1-Mediated CXCL12 Expression in Bladder Cancer Affects the Recruitment of Tumor‐associated Macrophages. Molecular Carcinogenesis, 63, 448-460. [Google Scholar] [CrossRef] [PubMed]
[33] Praharaj, M., Shen, F., Lee, A.J., Zhao, L., Nirschl, T.R., Theodros, D., et al. (2024) Metabolic Reprogramming of Tumor-Associated Macrophages Using Glutamine Antagonist JHU083 Drives Tumor Immunity in Myeloid-Rich Prostate and Bladder Cancers. Cancer Immunology Research, 12, 854-875. [Google Scholar] [CrossRef] [PubMed]
[34] Ouyang, Y., Ou, Z., Zhong, W., Yang, J., Fu, S., Ouyang, N., et al. (2023) FGFR3 Alterations in Bladder Cancer Stimulate Serine Synthesis to Induce Immune-Inert Macrophages That Suppress T-Cell Recruitment and Activation. Cancer Research, 83, 4030-4046. [Google Scholar] [CrossRef] [PubMed]
[35] Loriot, Y., Matsubara, N., Park, S.H., Huddart, R.A., Burgess, E.F., Houede, N., et al. (2023) Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. New England Journal of Medicine, 389, 1961-1971. [Google Scholar] [CrossRef] [PubMed]
[36] Wang, B., Zhou, B., Chen, J., Sun, X., Yang, W., Yang, T., et al. (2024) Type III Interferon Inhibits Bladder Cancer Progression by Reprogramming Macrophage-Mediated Phagocytosis and Orchestrating Effective Immune Responses. Journal for ImmunoTherapy of Cancer, 12, e007808. [Google Scholar] [CrossRef] [PubMed]
[37] Jia, W., Luo, S., Lai, G., Li, S., Huo, S., Li, M., et al. (2021) Homogeneous Polyporus Polysaccharide Inhibits Bladder Cancer by Polarizing Macrophages to M1 Subtype in Tumor Microenvironment. BMC Complementary Medicine and Therapies, 21, Article No. 150. [Google Scholar] [CrossRef] [PubMed]
[38] Liu, C., He, D., Zhang, S., Chen, H., Zhao, J., Li, X., et al. (2022) Homogeneous Polyporus Polysaccharide Inhibit Bladder Cancer by Resetting Tumor-Associated Macrophages toward M1 through NF-κB/NLRP3 Signaling. Frontiers in Immunology, 13, Article 839460. [Google Scholar] [CrossRef] [PubMed]
[39] Guo, P., Dai, P., Yang, S., Wang, Z., Tong, Z., Hou, D., et al. (2023) Engineered Macrophages Tune Intratumoral Cytokines through Precisely Controlled Self-Pyroptosis to Enhance Bladder Cancer Immunotherapy. Small, 20, Article 2306699. [Google Scholar] [CrossRef] [PubMed]
[40] Zhang, L., Xiao, Z., Zhang, D., Yang, L., Yuan, Z., Wang, G., et al. (2024) Targeted Initiation of Trained Immunity in Tumor-Associated Macrophages with Membrane-Camouflaged Bacillus Calmette-Guérin for Lung Carcinoma Immunotherapy. ACS Nano, 18, 34219-34234. [Google Scholar] [CrossRef] [PubMed]
[41] Xu, D., Wang, L., Wieczorek, K., Zhang, Y., Wang, Z., Wang, J., et al. (2022) Single-Cell Analyses of a Novel Mouse Urothelial Carcinoma Model Reveal a Role of Tumor-Associated Macrophages in Response to Anti-PD-1 Therapy. Cancers, 14, Article 2511. [Google Scholar] [CrossRef] [PubMed]
[42] Hu, B., Wang, Z., Zeng, H., Qi, Y., Chen, Y., Wang, T., et al. (2020) Blockade of DC-SIGN+ Tumor-Associated Macrophages Reactivates Antitumor Immunity and Improves Immunotherapy in Muscle-Invasive Bladder Cancer. Cancer Research, 80, 1707-1719. [Google Scholar] [CrossRef] [PubMed]
[43] Yang, M., Wang, B., Hou, W., Zeng, H., He, W., Zhang, X., et al. (2024) NAD+ Metabolism Enzyme NNMT in Cancer-Associated Fibroblasts Drives Tumor Progression and Resistance to Immunotherapy by Modulating Macrophages in Urothelial Bladder Cancer. Journal for ImmunoTherapy of Cancer, 12, e009281. [Google Scholar] [CrossRef] [PubMed]
[44] Qi, F., Bao, Q., Hu, P., Guo, Y., Yan, Y., Yao, X., et al. (2024) Mild Magnetic Hyperthermia-Activated Immuno-Responses for Primary Bladder Cancer Therapy. Biomaterials, 307, Article 122514. [Google Scholar] [CrossRef] [PubMed]
[45] Chuang, A.E.-Y., Tao, Y., Dong, S., Nguyen, H.T. and Liu, C. (2024) Polypyrrole/Iron-Glycol Chitosan Nanozymes Mediate M1 Macrophages to Enhance the X-Ray-Triggered Photodynamic Therapy for Bladder Cancer by Promoting Antitumor Immunity. International Journal of Biological Macromolecules, 280, Article 135608. [Google Scholar] [CrossRef] [PubMed]

为你推荐